Utilizes artificial intelligence and genomic data to develop precision oncology therapies, focusing on personalized medicine approaches.
Lantern Pharma Inc. is a pioneering clinical-stage biotechnology company leveraging artificial intelligence, machine learning, and genomic data to revolutionize drug development processes. At the forefront of its innovative pipeline is LP-100, currently in Phase II clinical trials for metastatic, castration-resistant prostate cancer. Complementing this, the company is advancing LP-300, envisioned as a combination therapy tailored for non-smokers and never-smokers diagnosed with non-small cell lung cancer adenocarcinoma. Additionally, Lantern Pharma is progressing LP-184, a promising preclinical alkylating agent designed to target cancer cells with specific biomarker overexpression or mutations in DNA repair pathways.
Beyond its core drug candidates, Lantern Pharma operates an ADC program focused on antibody drug conjugate therapies for cancer treatment. The company's proprietary artificial intelligence platform, RADR, harnesses big data analytics and machine learning to analyze molecular data comprehensively. This cutting-edge technology enhances the company's ability to identify optimal drug candidates and predict patient responses, thereby accelerating the development of innovative oncology treatments.
Founded in 2013 and headquartered in Dallas, Texas, Lantern Pharma Inc. is dedicated to transforming the landscape of cancer care through groundbreaking research and development initiatives. With a commitment to precision medicine and data-driven innovation, the company strives to address critical unmet needs in oncology, ultimately aiming to improve outcomes for patients worldwide.